SLGL News and Press, Sol-Gel Technologies Ltd. From 06/06/23

2023-06-06 12:42:07 ET Israel's Sol-Gel ( NASDAQ: SLGL ) has signed an exclusive licensing deal with Searchlight Pharma for the Canadian commercialization rights to its dermatology products Twyneo and Eposolay. Sol-Gel said it will receive up to $11M in upfront and milestone...

Sol-Gel to receive up to $11 million in upfront payment s and regulatory and sales milestone s for both drugs, combined, plus additional royalties ranging from low double-digits to high - teens Non -di lutive capital stre...

2023-05-12 07:31:54 ET Sol-Gel Technologies press release ( NASDAQ: SLGL ): Q1 GAAP EPS of -$0.41. Revenue of $0.76M. As of March 31, 2023, Sol-Gel had $20.3 million in cash, cash equivalents and deposits, and $18.4 million in marketable securities for a total balance ...

Positive trends continue for TWYNEO ® and EPSOLAY ® with recurrent prescriber base s at 98% for TWYNEO and 92% for EPSOLAY during Q1 2023 Sol-Gel on track to advance Orphan Drug candidate, SGT-610 (patidegib) fo...

2023-03-22 10:02:09 ET Gainers: 89bio ( ETNB ) +38% . SCYNEXIS ( SCYX ) +21% . Athersys ( ATHX ) +20% .  Sol-Gel Technologies ( SLGL ) +19% . LifeMD ( LFMD ) +11% . Losers: NuCana ( NCNA ) -10% . Nutex Hea...

NESS ZIONA, Israel, March 20, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company with two innovative dermatology products that were launched in the U.S. and an innovative pipeline, today announced that it will present at H.C. Wainwright’s Autoimmune &...

2023-03-10 07:39:20 ET Sol-Gel Technologies press release ( NASDAQ: SLGL ): FY GAAP EPS of -$0.65 misses by $0.15 . Revenue of $3.88M (-87.6% Y/Y) misses by $1.8M . As of December 31, 2022, Sol-Gel had $24.9million in cash, cash equival...

Recent acquisition of Phase 3-ready SGT-610 ( p atidegib ) , an Orphan Drug candidate, broadens Sol-Gel’s pipeline with the potential to be the first therapy for preventing new basal cell carcinomas in Gorlin syndrome A Phase 3 study of SGT-610...

Sol-Gel Technologies ( NASDAQ: SLGL ) said it is acquiring topically-applied drug patidegib from PellePharm, and separately announced $22.8M registered direct and private placement offerings. Sol-Gel will pay PellePharm $4.7M upfront and total development and NDA acceptance miles...

NESS ZIONA, Israel, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a dermatology company with FDA approvals for EPSOLAY ® and TWYNEO ® , two innovative dermatology products that were launched ...